logo
AI Icon𝛼SK or Search
ENTITY
GNI Group

GNI Group (2160 JP)

12
Analysis
Health Care • Japan
GNI Group Ltd. develops therapeutic pharmaceutical products utilizing Genome analysis. The Company targets diseases indigenous to Asian countries. GNI controls the whole process of drug discovery by conducting clinical trials, research and development, and marketing. The Company owns global subsidiaries in China and the US.
more
bullish•GNI Group
•05 Aug 2026 03:50

Primer: GNI Group (2160 JP) - Aug 2026

GNI Group is a biopharmaceutical company with an integrated business model focused on the high-growth Chinese market, where its flagship drug,...

Logo
αSK Primers
94 Views
Share
bullish•Thematic (Sector/Industry)
•24 Aug 2025 08:30

APAC Healthcare Weekly (Aug 24) – Wuxi Bio, Ab&B Bio, Ascletis Pharma, Remegen, Daiichi Sankyo, CSL

Wuxi Bio got EMA nod for Ireland manufacturing facility. Daiichi Sankyo got breakthrough therapy designation for its drug candidate in US. CSL...

Logo
Tina Banerjee
698 Views
Share
bullish•Thematic (Sector/Industry)
•15 Jun 2025 08:30

APAC Healthcare Weekly (June 15)- CSPC, Wuxi Bio, Samsung Bio, Daiichi Sankyo, SanBio, Cochlear

CSPC entered research collaboration with AstraZeneca. Wuxi Bio is constructing new plant in China. Samsung Bio signed new CDMO contract. Daiichi...

Logo
Tina Banerjee
581 Views
Share
bullish•Thematic (Sector/Industry)
•08 Jun 2025 08:30

APAC Healthcare Weekly (June 8)- Hansoh Pharma, Daiichi Sankyo, Takeda, Mayne Pharma, Zydus Life

Hansoh stuck deal with Regeneron for obesity drug candidate. Daiichi Sankyo unveiled positive phase 3 trial result in first-line breast cancer....

Logo
Tina Banerjee
963 Views
Share
bullish•Thematic (Sector/Industry)
•28 Dec 2018 17:53

Japan Pharma - Top Picks (28 Dec 2018)

                                                                                                                                                   ...

Logo
Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x